Last reviewed · How we verify
Sinopharm BIBP
Sinopharm BIBP is a COVID-19 inactivated vaccine that stimulates immune responses against SARS-CoV-2 by presenting inactivated viral particles to the immune system.
Sinopharm BIBP is a COVID-19 inactivated vaccine that stimulates immune responses against SARS-CoV-2 by presenting inactivated viral particles to the immune system. Used for COVID-19 prevention in adults and pediatric populations.
At a glance
| Generic name | Sinopharm BIBP |
|---|---|
| Sponsor | Vaxxinity, Inc. |
| Drug class | Inactivated viral vaccine |
| Target | SARS-CoV-2 spike protein and other viral antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) SARS-CoV-2 virus particles, which cannot cause infection but trigger both humoral (antibody) and cellular immune responses. This approach allows the body to develop protective immunity against the virus without risk of active infection. The vaccine is administered intramuscularly in a multi-dose series to establish and maintain protective antibody titers.
Approved indications
- COVID-19 prevention in adults and pediatric populations
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea (PHASE2)
- Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine (PHASE3)
- Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines (PHASE2)
- mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs (PHASE3)
- Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine (PHASE3)
- Combination Assessment Trial of COVID-19 Vaccines (COMBAT-COVID) (PHASE2)
- Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain
- Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sinopharm BIBP CI brief — competitive landscape report
- Sinopharm BIBP updates RSS · CI watch RSS
- Vaxxinity, Inc. portfolio CI